A novel method for the detection of down syndrome with the use of four serum markers

Azuma, Masaki; Yamamoto, Ritsu; Wakui, Yukio; Minobe, Shinichiro; Satomura, Shinji; Fujimoto, Seiichiro

doi:10.1067/mob.2002.123201

Cited by 10 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Conde-Agudelo & Kafury-Goeta 1998). In our previous study, the screening using AFP-L3% with AFP MoM, hCG MoM, and uE3 MoM showed that the sensitivity can be raised to 80% or higher, with a 5% false positive rate (Azuma et al 2002). In this study, AFP-L3% was measured by lectinaffinity electrophoresis coupled with antibody-affinity blotting (Shimizu et al 1996), limiting the weeks of gestation useful for analysis from 14 to 20, which differed from the method used in the present study.…”

Section: Discussionmentioning

confidence: 72%

“…(Conde‐Agudelo & Kafury‐Goeta 1998). In our previous study, the screening using AFP‐L3% with AFP MoM, hCG MoM, and uE3 MoM showed that the sensitivity can be raised to 80% or higher, with a 5% false positive rate (Azuma et al . 2002).…”

Section: Discussionmentioning

confidence: 98%

“…Therefore, we ignored differences in weeks of gestation when examining the efficacy of AFP‐L3% in the previous study (Yamamoto et al . 2001a; Azuma et al . 2002).…”

Section: Discussionmentioning

confidence: 99%

“…15-17 weeks), we were unable to observe any significant difference in AFP-L3%. Therefore, we ignored differences in weeks of gestation when examining the efficacy of AFP-L3% in the previous study (Yamamoto et al 2001a;Azuma et al 2002). However, when conducting a comparative analysis of a factor that gradually changes as pregnancy advances, evaluation by MoM is logically the better choice.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prenatal trisomy 21 screening using the Lens culinaris agglutinin‐reactive alpha‐fetoprotein ratio

Yamamoto

Minobe

Ebina

et al. 2004

Congenital Anomalies

Self Cite

View full text Add to dashboard Cite

For the purpose of improving the clinical efficacy of alpha-fetoprotein (AFP)-L3% in prenatal screening for trisomy 21, we calculated the multiple of the median (MoM) of AFP-L3% (L3 MoM) and the ratio of L3 MoM to AFP MoM (L3 MoM/AFP MoM) in maternal serum. Maternal serum samples from 1822 women (maternal age 37.3 +/- 3.8 years, and weeks of gestation 16.0 +/- 1.0; mean +/- SD) with unaffected pregnancies and 28 women (37.6 +/- 4.6 years, 16.6 +/- 3.1) pregnant with of trisomy 21 fetuses were obtained. The AFP concentration and AFP-L3% in maternal serum were measured using a liquid-phase binding assay. The areas under the receiver operating characteristic curves (AUCs) of AFP MoM, AFP-L3%, L3 MoM, and L3 MoM/AFP MoM were 0.750, 0.868, 0.949 and 0.946, respectively. The AUCs of L3 MoM and L3 MoM/AFP MoM were significantly higher than AFP-L3% (P < 0.05) and AFP MoM (P < 0.0005). However, no statistical difference was observed between the AUCs of L3 MoM and L3 MoM/AFP MoM. In conclusion, the L3 MoM should be an effective replacement for AFP-L3% in prenatal trisomy 21 screening.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 98%

“…Therefore, we ignored differences in weeks of gestation when examining the efficacy of AFP‐L3% in the previous study (Yamamoto et al . 2001a; Azuma et al . 2002).…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prenatal trisomy 21 screening using the Lens culinaris agglutinin‐reactive alpha‐fetoprotein ratio

Yamamoto

Minobe

Ebina

et al. 2004

Congenital Anomalies

Self Cite

View full text Add to dashboard Cite

show abstract

“…In recent years, we have reported that the percentage of AFP that strongly binds to Lens culinaris agglutinin (LCA) (AFP‐L3) in the maternal serum of pregnancies with a trisomy 21 fetus is significantly higher than that present in normal pregnancies, and the measurement of AFP‐L3 in maternal serum is a potential biochemical marker for trisomy 21 fetus in the second trimester of pregnancy (3–5). The AFP‐L3 variant is known to have an additional fucose residue on N‐acetylglucosamine (GlcNAc) at the reducing end (6).…”

mentioning

confidence: 99%

A study of oligosaccharide variants of alpha‐fetoproteins produced by normal fetuses and fetuses with trisomy 21

Yamamoto

Ohkouchi

Tabata

et al. 2005

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

show abstract

Second trimester serum tests for Down's Syndrome screening

Alldred

Deeks

Guo

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Down's syndrome occurs when a person has three copies of chromosome 21-or the specific area of chromosome 21 implicated in causing Down's syndrome-rather than two. It is the commonest congenital cause of mental retardation. Noninvasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being a ected and provides information to guide decisions about definitive testing. Objectives To estimate and compare the accuracy of second trimester serum markers for the detection of Down's syndrome.

show abstract

A novel method for the detection of down syndrome with the use of four serum markers

Cited by 10 publications

References 22 publications

Prenatal trisomy 21 screening using the Lens culinaris agglutinin‐reactive alpha‐fetoprotein ratio

Prenatal trisomy 21 screening using the Lens culinaris agglutinin‐reactive alpha‐fetoprotein ratio

A study of oligosaccharide variants of alpha‐fetoproteins produced by normal fetuses and fetuses with trisomy 21

Second trimester serum tests for Down's Syndrome screening

Contact Info

Product

Resources

About